Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 11/20 | 0.74 |
| ▸ | PPARA | Q07869 | 8/20 | 0.48 |
| ▸ | PPARG | P37231 | 7/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6474881 | 0.87 | PPARD (0.72) | PPARDPPARAPPARGMAOBCYP4F2 | |
| SCHEMBL6474338 | 0.85 | PPARD (1.00) | PPARDPPARAPPARGALDH1A1HPGD | |
| SCHEMBL10444982 | 0.79 | PPARA (0.61) | PPARAPPARGCYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL6475650 | 0.78 | PPARD (0.71) | PPARDPPARAPPARGMAOB | |
| SCHEMBL6473138 | 0.77 | PPARD (0.56) | PPARDPPARAPPARGTP53MAOA | |
| SCHEMBL6473129 | 0.77 | PPARD (0.56) | PPARDPPARAPPARGTP53MAOA | |
| SCHEMBL6473132 | 0.77 | PPARD (0.56) | PPARDPPARAPPARGTP53MAOA | |
| SCHEMBL6475169 | 0.76 | PPARD (0.69) | PPARDPPARAPPARG | |
| SCHEMBL6475165 | 0.76 | PPARD (0.69) | PPARDPPARAPPARG | |
| SCHEMBL6475171 | 0.76 | PPARD (0.69) | PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869967-B2 | Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | claimed |
| EP-1414778-A1 | NOVEL VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC. | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | EP | claimed |
| US-20030139473-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-07-24 | — | — | US | claimed |
| WO-2003011807-A1 | NOVEL VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC. | NOVO NORDISK A/S (DK) | 2003-02-13 | — | — | WO | claimed |
| US-6869967-B2 | Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | disclosed |
| EP-1414778-A1 | NOVEL VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC. | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | EP | disclosed |
| US-20030139473-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-07-24 | — | — | US | disclosed |
| WO-2003011807-A1 | NOVEL VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC. | NOVO NORDISK A/S (DK) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139473-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | PPARD 2/4885PPARA 3/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.